恩度联合DP化疗方案治疗晚期非小细胞肺癌的临床研究

郭维新; 杨权烈

恩度联合DP化疗方案治疗晚期非小细胞肺癌的临床研究

广东省梅州市人民医院化疗一科,广东梅州,514031

基金项目: 中国高校医学期刊临床专项资金

详细信息

中图分类号: R734.2
计量
- 文章访问数: 249
- HTML全文浏览量: 25
- PDF下载量: 6
出版历程
- 发布日期: 2013-02-27

A feasibility study of endostar combined with platinum-based DP chemotherapy in the treatment of advanced non-small cell lung cancer

摘要

摘要: 目的探讨恩度联合DP化疗方案(多西紫杉醇+顺铂)治疗晚期非小细胞肺癌患者的近期临床疗效,评价其临床应用的安全性和耐受性.方法 45例晚期非小细胞肺癌患者给予DP方案化疗同时联合恩度7.5 mg/m2,连用2周后暂停1周为1周期,至少完成2周期,观察近期疗效、疾病进展时间及不良反应.结果 45例患者中部分缓解18例(40.0％),稳定17例(37.8％),进展10例(22.2％),有效率为40.0％,临床受益率为77.8％.不良反应主要为骨髓抑制和胃肠反应,患者经对症处理后可以耐受.结论恩度联合含铂类DP化疗方案一线治疗晚期非小细胞肺癌是一种安全有效的方案.
- 非小细胞肺癌 /
- 恩度 /
- 联合化疗 /
- DP方案

HTML全文

参考文献(11)

Takigawa N, Kiura K, Segawa Y. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer:analysis of the Okayama Lung Cancer Study Group trial 0007 [J]. JOURNAL OF THORACIC ONCOLOGY, 2011(6):1087.

Ge W, Cao DD, Wang HM. Endostar Combined with Chemotherapy Versus Chemotherapy Alone for Advanced NSCLCs:A Meta-analysis [J]. Asian Pacific Journal of Cancer Prevention, 2011, (11):2901.

Goffin J, Lacchetti C, Ellis PM. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer:a systematic review [J]. JOURNAL OF THORACIC ONCOLOGY, 2010(2):260.

Yan Y, Xu W, Qian H. Tumstatin45-132-TNFalpha suppresses tumour growth through anti-angiogenic effects and cytotoxicity [J]. Biotechnology and Applied Biochemistry, 2010(3):119.

Thevenard J, Ramont L, Devy J. The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration [J]. International Journal of Cancer, 2010(5):1055.

Ling Y, Yang Y, Lu N. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells [J]. Biochemical and Biophysical Research Communications, 2007(1):79.

Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action [J]. Experimental Cell Research, 2006(5):594.

Han B, Xiu Q, Wang H. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer [J]. JOURNAL OF THORACIC ONCOLOGY, 2011(6):1104.

王知非, 董海英. 内皮抑素恩度联合化疗对入肝癌细胞作用研究 [J]. 哈尔滨医科大学学报, 2011(6):533.

Rosca EV, Koskimaki JE, Rivera CG. Anti-angiogenic peptides for cancer therapeutics [J]. Current Pharmaceutical Biotechnology, 2011(8):1101.

高文斌, 吕金燕, 王若雨. 重组人血管内皮抑素的临床疗效及不良反应 [J]. 药物不良反应杂志, 2007(1):32.doi: 10.3969/j.issn.1008-5734.2007.01.009.

施引文献

资源附件(0)

计量

文章访问数: 249
HTML全文浏览量: 25
PDF下载量: 6
被引次数: 0

恩度联合DP化疗方案治疗晚期非小细胞肺癌的临床研究

计量

出版历程

A feasibility study of endostar combined with platinum-based DP chemotherapy in the treatment of advanced non-small cell lung cancer

计量

出版历程

目录